Create an account

Already have an account?
Technical support
Send
The password is: uppercase and lowercase English letters and numbers, no less than 6 characters
Submit

Login

Don’t have an account? Sign up
Forgot password?
Login
Press Releases
All
  • All
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
AmoyDx® Essential NGS panel approval from Chinese authority

AmoyDx® Essential NGS panel approval from Chinese authority

AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell

AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib

AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib

Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.

China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit

China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit

(January 22, 2018, Xiamen China)  Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685)  announced that NMPA(National Medical Products Administration)approved AmoyDx Super-ARMS® EGFR mutation test kit

Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?

Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?

Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy

Amoy Diagnostics Co., Ltd. achieved IPO on Shenzhen Stock Exchange

Amoy Diagnostics Co., Ltd. achieved IPO on Shenzhen Stock Exchange

August 2, 2017 Shenzhen, China. Amoy Diagnostics Co., Ltd. (AmoyDx), a Xiamen-based biotechnology firm became a public company today with ShenZhen Stock Exchange (SZSE) code 300685 and began trading.

AmoyDx attended News Conference of Xalkori ROS1 approval in Japan

AmoyDx attended News Conference of Xalkori ROS1 approval in Japan

On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.

AmoyDx to develop CDx for CANbridge Glioblastoma Candidate

AmoyDx to develop CDx for CANbridge Glioblastoma Candidate

CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n

AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients

AmoyDx HER2 Mutation Test Acting as Companion Diagnostics for Boehringer Ingelheim's Afatinib Study in NSCLC Patients

Recently Boehringer Ingelheim launched a Phase II study of Afatinib (Identifier: NCT02597946) to evaluate its efficacy and safety in advanced patients with advanced Non-Small Cell Lung Cancer (NSCLC)

AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib

AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib

February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a

Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China

Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China

· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple

AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer

AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer

June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported

Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit

Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit

Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection

Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China

Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China

XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine

Subscribe
to our
newsletter

Subscribe to our newsletter

Subscribe Now